Krijtenburg, Piet
de Boer, Arjen
Bash, Lori D.
Scheffer, Gert Jan
Keijzer, Christiaan
Warlé, Michiel C.
Article History
Received: 14 April 2022
Accepted: 22 March 2024
First Online: 27 March 2024
Declarations
:
: Ethical approval for this study (Ethical Committee N° 2022-13646) was provided by the Medical Research Ethical Committee Oost-Nederland, Philips van Leydenlaan 25, Nijmegen, the Netherlands (Chairperson Prof. Dr. P.N.R. Dekhuijzen,) on 22 march 2022. Written patient informed consent was waived for this study because there were no care interventions and no direct patient identifiers were used for analysis. However, surgical cases were checked if the data could be used for research purposes by opt-out consent for the use of medical data for scientific purposes registered in the EMR.
: Not applicable.
: MCW has received research grants from Merck Sharp & Dohme, Bayer, and Grünenthal, outside the submitted work. LDB is a full-time employee of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA which manufactures and distributes sugammadex, and may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ. The other authors (PK, CK, AB, GJS) have nothing to disclose.